M&A Deal Summary

Kindeva Drug Delivery Acquires Summit Biosciences

On January 18, 2024, Kindeva Drug Delivery acquired life science company Summit Biosciences

Acquisition Highlights
  • This is Kindeva Drug Delivery’s 1st transaction in the Life Science sector.
  • This is Kindeva Drug Delivery’s 1st transaction in the United States.
  • This is Kindeva Drug Delivery’s 1st transaction in Kentucky.

M&A Deal Summary
Date 2024-01-18
Target Summit Biosciences
Sector Life Science
Buyer(s) Kindeva Drug Delivery
Deal Type Add-on Acquisition
Advisor(s) Bourne Partners Investment Banking (Financial)
Frost Brown Todd (Legal)

Target

Summit Biosciences

Lexington, Kentucky, United States
Summit Biosciences is an intranasal drug-delivery contract development and manufacturing organization. Summit Biosciences was founded in 2009 and is based in Lexington, Kentucky.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kindeva Drug Delivery

Woodbury, Minnesota, United States
Category Company
Founded 2020
Sector Life Science
DESCRIPTION

Kindeva Drug Delivery engages in drug delivery that partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using its unique inhalation, transdermal, microneedle, or conventional drug delivery technologies. Kindeva Drug Delivery was formed in 2020 and is based in Woodbury, Minnesota.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Kentucky) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal